Method
Level · gp.fundamentals.debt_to_revenue
Raw value 164.93% · OPTIONAL
· Surgical & Medical Instruments & Apparatus
RESEARCH SNAPSHOTPulmonx Corp's latest supported as-filed period reports revenue of $22.8M; gross margin moved 586 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 164.93% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -22.91% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -4.62% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 72.02% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 77.97% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 1.3%; Inventory / revenue moved 423 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Debt increased 1.1%; Cash & equivalents decreased 26.0%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 26.0%; Debt increased 1.1%.
2 evidence-backed componentsOperating income changed +38.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LUNG · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001805624-26-000004SEC ↗4Sep 3, 2026Period Sep 1, 20260002098678-26-000004SEC ↗4Sep 3, 2026Period Sep 1, 20260001354228-26-000005SEC ↗4Sep 3, 2026Period Sep 1, 20260001804146-26-000004SEC ↗10-QAug 4, 2026Period Jun 30, 20260001127537-26-000039SEC ↗8-KJul 29, 2026Period Jul 29, 20260001127537-26-000035SEC ↗4Jun 9, 2026Period Jun 5, 20260001644557-26-000022SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 1, 2026Filed Sep 3, 2026 | Rose Geoffrey BeranChief Commercial Officer | Open Market SaleDirect | 2,213 | $2 | $5,001 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Rose Geoffrey BeranChief Commercial Officer | Open Market SaleDirect | 2,390 | $2 | $5,401 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Rose Geoffrey BeranChief Commercial Officer | Open Market SaleDirect | 1,530 | $2 | $3,458 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Rose Geoffrey BeranChief Commercial Officer | Open Market SaleDirect | 1,746 | $2 | $3,946 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value -39.80% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 22.12% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 16.25% · OPTIONAL
Operating margin changed +2225 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Gross margin changed +586 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed -40.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
SBC / revenue changed -979 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Selling, general & administrative changed -18.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed +33.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001034413-26-000002| Sep 1, 2026Filed Sep 3, 2026 |
| Radhakrishnan SrikanthChief Science & Techn. Officer |
| Open Market SaleDirect |
| 2,643 |
| $2 |
| $5,973 |
| Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Radhakrishnan SrikanthChief Science & Techn. Officer | Open Market SaleDirect | 2,121 | $2 | $4,793 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Radhakrishnan SrikanthChief Science & Techn. Officer | Open Market SaleDirect | 3,618 | $2 | $8,177 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Radhakrishnan SrikanthChief Science & Techn. Officer | Open Market SaleDirect | 5,863 | $2 | $13,250 | Form 4 ↗ |
| Jun 5, 2026Filed Jun 9, 2026 | Burns Thomas WilliamDirector | Grant Or AwardDirect | 40,000 | $0 | $0 | Form 4 ↗ |